Antitumor Effects of Ral-GTPases Downregulation in Glioblastoma.

Glioblastoma (GBM) is the most common tumor in the central nervous system in adults. This neoplasia shows a high capacity of growth and spreading to the surrounding brain tissue, hindering its complete surgical resection. Therefore, the finding of new antitumor therapies for GBM treatment is a prior...

Descripción completa

Detalles Bibliográficos
Autores: Cemeli, Tània, Guasch Vallés, Marta, Ribes Santolaria, Marina, Ibars Estiarte, Eva Irene, Navaridas Fernández de Bobadilla, Raúl, Dolcet Roca, Xavier, Pedraza González, Neus, Colomina i Gabarrella, Neus, Torres Rosell, Jordi, Ferrezuelo, Francisco, Herreros Danés, Judit, Garí Marsol, Eloi
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Universitat de Lleida (UdL)
Repositorio:Repositori Obert UdL
OAI Identifier:oai:repositori.udl.cat:10459.1/83786
Acceso en línea:https://doi.org/10.3390/ijms23158199
http://hdl.handle.net/10459.1/83786
Access Level:acceso abierto
Palabra clave:Glioma
Glioblastoma
Ral-GTPases
RalB
Recurrence
Therapy
id ES_e0c3d73d747215c62e8d7b7de4e3099e
oai_identifier_str oai:repositori.udl.cat:10459.1/83786
network_acronym_str ES
network_name_str España
repository_id_str
spelling Antitumor Effects of Ral-GTPases Downregulation in Glioblastoma.Cemeli, TàniaGuasch Vallés, MartaRibes Santolaria, MarinaIbars Estiarte, Eva IreneNavaridas Fernández de Bobadilla, RaúlDolcet Roca, XavierPedraza González, NeusColomina i Gabarrella, NeusTorres Rosell, JordiFerrezuelo, FranciscoHerreros Danés, JuditGarí Marsol, EloiGliomaGlioblastomaRal-GTPasesRalBRecurrenceTherapyGlioblastoma (GBM) is the most common tumor in the central nervous system in adults. This neoplasia shows a high capacity of growth and spreading to the surrounding brain tissue, hindering its complete surgical resection. Therefore, the finding of new antitumor therapies for GBM treatment is a priority. We have previously described that cyclin D1-CDK4 promotes GBM dissemination through the activation of the small GTPases RalA and RalB. In this paper, we show that RalB GTPase is upregulated in primary GBM cells. We found that the downregulation of Ral GTPases, mainly RalB, prevents the proliferation of primary GBM cells and triggers a senescence-like response. Moreover, downregulation of RalA and RalB reduces the viability of GBM cells growing as tumorspheres, suggesting a possible role of these GTPases in the survival of GBM stem cells. By using mouse subcutaneous xenografts, we have corroborated the role of RalB in GBM growth in vivo. Finally, we have observed that the knockdown of RalB also inhibits cell growth in temozolomide-resistant GBM cells. Overall, our work shows that GBM cells are especially sensitive to Ral-GTPase availability. Therefore, we propose that the inactivation of Ral-GTPases may be a reliable therapeutic approach to prevent GBM progression and recurrence.This work was funded by the Catalan Government—AGAUR (2017 SGR-569), Ministerio de Ciencia e Innovaciön (PID2019-104859GB-I00; RTI2018-094739-B-I00; PID2019-104734RB-I00), and by the Xarxa de Bancs de Tumors de Catalunya sponsored by Pla Director d’Oncologia de Catalunya (XBTC). T Cemeli (FPU13/06590), M.Guasch (FPU17/00229), R. Navaridas (FPU18/04480), and M. Ribes (TALENT-IRBLleida) were supported by a pre-doctoral fellowship from Ministerio de Educación, Cultura y Deportes, and from Diputació de Lleida.MDPI2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://doi.org/10.3390/ijms23158199http://hdl.handle.net/10459.1/83786reponame:Repositori Obert UdL instname:Universitat de Lleida (UdL)Inglésinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2019-104859GB-I00info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-094739-B-I00info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2019-104734RB-I00Reproducció del document publicat a: https://doi.org/10.3390/ijms23158199International Journal Of Molecular Sciences, 2022, vol. 23, núm. 15, p. 8199cc-by (c) Cemeli, Tània et al., 2022info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/4.0/oai:repositori.udl.cat:10459.1/837862026-06-24T12:42:17Z
dc.title.none.fl_str_mv Antitumor Effects of Ral-GTPases Downregulation in Glioblastoma.
title Antitumor Effects of Ral-GTPases Downregulation in Glioblastoma.
spellingShingle Antitumor Effects of Ral-GTPases Downregulation in Glioblastoma.
Cemeli, Tània
Glioma
Glioblastoma
Ral-GTPases
RalB
Recurrence
Therapy
title_short Antitumor Effects of Ral-GTPases Downregulation in Glioblastoma.
title_full Antitumor Effects of Ral-GTPases Downregulation in Glioblastoma.
title_fullStr Antitumor Effects of Ral-GTPases Downregulation in Glioblastoma.
title_full_unstemmed Antitumor Effects of Ral-GTPases Downregulation in Glioblastoma.
title_sort Antitumor Effects of Ral-GTPases Downregulation in Glioblastoma.
dc.creator.none.fl_str_mv Cemeli, Tània
Guasch Vallés, Marta
Ribes Santolaria, Marina
Ibars Estiarte, Eva Irene
Navaridas Fernández de Bobadilla, Raúl
Dolcet Roca, Xavier
Pedraza González, Neus
Colomina i Gabarrella, Neus
Torres Rosell, Jordi
Ferrezuelo, Francisco
Herreros Danés, Judit
Garí Marsol, Eloi
author Cemeli, Tània
author_facet Cemeli, Tània
Guasch Vallés, Marta
Ribes Santolaria, Marina
Ibars Estiarte, Eva Irene
Navaridas Fernández de Bobadilla, Raúl
Dolcet Roca, Xavier
Pedraza González, Neus
Colomina i Gabarrella, Neus
Torres Rosell, Jordi
Ferrezuelo, Francisco
Herreros Danés, Judit
Garí Marsol, Eloi
author_role author
author2 Guasch Vallés, Marta
Ribes Santolaria, Marina
Ibars Estiarte, Eva Irene
Navaridas Fernández de Bobadilla, Raúl
Dolcet Roca, Xavier
Pedraza González, Neus
Colomina i Gabarrella, Neus
Torres Rosell, Jordi
Ferrezuelo, Francisco
Herreros Danés, Judit
Garí Marsol, Eloi
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Glioma
Glioblastoma
Ral-GTPases
RalB
Recurrence
Therapy
topic Glioma
Glioblastoma
Ral-GTPases
RalB
Recurrence
Therapy
description Glioblastoma (GBM) is the most common tumor in the central nervous system in adults. This neoplasia shows a high capacity of growth and spreading to the surrounding brain tissue, hindering its complete surgical resection. Therefore, the finding of new antitumor therapies for GBM treatment is a priority. We have previously described that cyclin D1-CDK4 promotes GBM dissemination through the activation of the small GTPases RalA and RalB. In this paper, we show that RalB GTPase is upregulated in primary GBM cells. We found that the downregulation of Ral GTPases, mainly RalB, prevents the proliferation of primary GBM cells and triggers a senescence-like response. Moreover, downregulation of RalA and RalB reduces the viability of GBM cells growing as tumorspheres, suggesting a possible role of these GTPases in the survival of GBM stem cells. By using mouse subcutaneous xenografts, we have corroborated the role of RalB in GBM growth in vivo. Finally, we have observed that the knockdown of RalB also inhibits cell growth in temozolomide-resistant GBM cells. Overall, our work shows that GBM cells are especially sensitive to Ral-GTPase availability. Therefore, we propose that the inactivation of Ral-GTPases may be a reliable therapeutic approach to prevent GBM progression and recurrence.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://doi.org/10.3390/ijms23158199
http://hdl.handle.net/10459.1/83786
url https://doi.org/10.3390/ijms23158199
http://hdl.handle.net/10459.1/83786
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2019-104859GB-I00
info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-094739-B-I00
info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2019-104734RB-I00
Reproducció del document publicat a: https://doi.org/10.3390/ijms23158199
International Journal Of Molecular Sciences, 2022, vol. 23, núm. 15, p. 8199
dc.rights.none.fl_str_mv cc-by (c) Cemeli, Tània et al., 2022
info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/4.0/
rights_invalid_str_mv cc-by (c) Cemeli, Tània et al., 2022
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositori Obert UdL
instname:Universitat de Lleida (UdL)
instname_str Universitat de Lleida (UdL)
reponame_str Repositori Obert UdL
collection Repositori Obert UdL
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422232252448768
score 15.812455